Doximity (NYSE:DOCS) Given New $27.00 Price Target at Needham & Company LLC

Doximity (NYSE:DOCS) had its price objective lowered by equities research analysts at Needham & Company LLC from $55.00 to $27.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 14.82% from the stock’s previous close.

DOCS has been the topic of a number of other research reports. Morgan Stanley reissued an “overweight” rating and issued a $35.00 target price (down from $49.00) on shares of Doximity in a research report on Thursday. Piper Sandler lifted their target price on Doximity from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. dropped their target price on Doximity from $40.00 to $33.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th. Wells Fargo & Company set a $18.00 target price on Doximity in a research report on Thursday. Finally, Barclays lowered their price target on Doximity from $63.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.60.

Doximity Stock Down 11.1%

Shares of DOCS stock opened at $23.52 on Thursday. The firm has a market cap of $4.34 billion, a P/E ratio of 19.60, a P/E/G ratio of 1.88 and a beta of 1.36. The business’s 50 day moving average is $24.27. Doximity has a 52 week low of $20.55 and a 52 week high of $76.51.

Doximity declared that its Board of Directors has approved a stock buyback program on Thursday, February 5th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to repurchase up to 8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Insider Activity at Doximity

In other news, Director Kira Scherer Wampler sold 9,000 shares of Doximity stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the completion of the transaction, the director directly owned 19,839 shares in the company, valued at approximately $517,004.34. The trade was a 31.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,427 shares of Doximity stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $21.09, for a total value of $51,185.43. Following the transaction, the insider owned 86,705 shares of the company’s stock, valued at $1,828,608.45. This represents a 2.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,055 shares of company stock valued at $456,061 over the last quarter. 31.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DOCS. Vanguard Group Inc. boosted its stake in Doximity by 4.1% in the 4th quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after purchasing an additional 518,916 shares during the period. William Blair Investment Management LLC boosted its stake in Doximity by 11.7% in the 3rd quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares during the period. Capital World Investors boosted its stake in Doximity by 5.1% in the 4th quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock valued at $250,398,000 after purchasing an additional 273,444 shares during the period. Franklin Resources Inc. boosted its stake in Doximity by 6.2% in the 3rd quarter. Franklin Resources Inc. now owns 3,357,505 shares of the company’s stock valued at $245,601,000 after purchasing an additional 194,912 shares during the period. Finally, Invesco Ltd. boosted its stake in Doximity by 4.2% in the 4th quarter. Invesco Ltd. now owns 2,426,819 shares of the company’s stock valued at $107,460,000 after purchasing an additional 98,519 shares during the period. 87.19% of the stock is currently owned by institutional investors.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted earnings of $0.26 per share, beating the lower analyst estimate of $0.17, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. Doximity Earnings Report
• Neutral Sentiment: The company’s high margin profile remained intact, with a 23.84% return on equity and 37.54% net margin, suggesting continued operational efficiency. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Despite the earnings beat versus one estimate, Doximity missed the broader Zacks consensus of $0.28 per share, which may have disappointed traders looking for a stronger beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: More importantly for investors, Doximity’s first-quarter FY2027 revenue guidance of $151 million to $152 million came in below the $153.2 million consensus, and full-year FY2027 revenue guidance of $664 million to $676 million also missed the $696 million estimate, signaling a softer outlook. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: The stock also faced added caution from an insider sale earlier in the week, though it was disclosed as part of a pre-arranged 10b5-1 plan and tax withholding related to equity vesting. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.